Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)
Author(s) -
Li Chen,
Hongming Zhu,
Yan Li,
Qi-Fa Liu,
Yu Hu,
Jian-Feng Zhou,
Jie Jin,
Jian-Da Hu,
Ting Liu,
Depei Wu,
Jie-Ping Chen,
Yong-Rong Lai,
Jianxiang Wang,
Juan Li,
Jian-Yong Li,
Xin Du,
Xin Wang,
Ming-Zhen Yang,
Jinsong Yan,
Gui-Fang Ouyang,
Li Liu,
Ming Hou,
XiaoJun Huang,
Xiao-Jing Yan,
Dan Xu,
WeiMing Li,
Deng-Ju Li,
Yinjun Lou,
Zheng-Jun Wu,
Ting Niu,
Ying Wang,
Xiaoyang Li,
Jian-Hua You,
Hui-Jin Zhao,
Yú Chen,
Yang Shen,
Qiu-Sheng Chen,
Jian Li,
Bingshun Wang,
Weili Zhao,
JianQing Mi,
Kankan Wang,
Jiong Hu,
Zhu Chen,
SaiJuan Chen,
Jun-Min Li
Publication year - 2021
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2020382118
Subject(s) - arsenic trioxide , medicine , acute promyelocytic leukemia , regimen , clinical trial , chemotherapy , randomized controlled trial , oncology , adverse effect , chemotherapy regimen , intensive care medicine , retinoic acid , arsenic , biochemistry , materials science , chemistry , metallurgy , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom